Autoimmune diseases in HIV-negative cryptococcal meningitis.

Area of Science:

• Infectious Diseases
• Immunology
• Neurology

Background:

• Cryptococcal meningitis (CM) is a serious opportunistic infection, particularly in immunocompromised individuals.
• Understanding the interplay between CM and autoimmune diseases is crucial for effective management.
• Previous research has not fully elucidated the specific clinical characteristics and treatment considerations for HIV-negative CM patients with co-existing autoimmune conditions.

Purpose of the Study:

• To compare clinical and laboratory findings in HIV-negative patients with cryptococcal meningitis (CM) who have autoimmune diseases versus those without.
• To identify potential differences in disease presentation, management, and outcomes between these two groups.
• To inform therapeutic strategies for CM in the context of autoimmune comorbidities.

Main Methods:

• Retrospective analysis of 43 HIV-negative CM patients with autoimmune diseases and 67 without.
• Comparison of clinical symptoms, laboratory markers (e.g., C-reactive protein, erythrocyte sedimentation rate), cerebrospinal fluid parameters (pressure, fungal counts), and treatment modalities.
• Evaluation of outcomes, sequelae, and mortality hazard, with subgroup analysis by gender.

Main Results:

• CM patients with autoimmune diseases presented with higher fever, elevated inflammation markers (CRP, ESR), and higher modified Rankin Scale scores.
• These patients exhibited lower rates of visual/hearing symptoms, fewer ventriculoperitoneal shunts, reduced MRI meningeal enhancement, and lower CSF pressure and fungal burden.
• No significant differences in overall outcomes, sequelae, or mortality were observed; fluconazole was a prognostic factor in non-autoimmune CM patients.

Conclusions:

• HIV-negative CM patients with autoimmune diseases display a unique clinical and laboratory profile compared to those without.
• Lower intracranial pressure and fungal burden in the autoimmune group suggest potential differences in host-pathogen interaction or inflammatory response.
• Therapeutic strategies for CM in patients with autoimmune diseases should judiciously incorporate both antifungal and anti-inflammatory treatments.